Activists and politicians have responded to the worldwide COVID-19 pandemic by calling for the elimination of patent rights on treatments or cures. Some have even called for outright confiscation by the government of any patents on tests, treatments, and vaccines. This teleforum will discuss how the biopharmaceutical industry has responded to the COVID-19 pandemic and consider the role played by reliable and effective patent rights in biotech innovations in making this response possible.
Are patents and patent licensing, including the licensing of university-patented inventions through the Bayh-Dole regime, essential legal and economic drivers of successful innovation in 21st-century healthcare? How might patents, patent licensing, and the tech transfer process created by the Bayh-Dole Act provide key legal and policy tools for companies to respond effectively to our current health crisis and crises to come? These and other questions will be discussed in this teleforum.
- Lesley Millar-Nicholson, Director, Technology Licensing Office & Director, Catalysts, Office of Strategic Alliances & Technology Transfer, MIT
- Brian P. O'Shaughnessy, Partner, Dinsmore & Shohl LLP and Past President, Licensing Executives Society, USA & Canada
- Corey Salsberg, Vice President, Global Head IP Affairs, Novartis
- [Moderator] Adam Mossoff, Professor of Law, Antonin Scalia Law School, George Mason University
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.